Cormorant Asset Management’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

Cormorant Asset Management’s Portfolio FMTX Stock Details FMTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,172,204	Closed	-$21.9M	–	85
2022 Q2	$21.9M	Sell	3,172,204 -896,147	-22%	-$6.29M	1.65%	21
2022 Q1	$37.8M	Sell	4,068,351 -571,644	-12%	-$6.08M	2.91%	10
2021 Q4	$66M	Sell	4,639,995 -80,500	-2%	-$1.39M	3.92%	5
2021 Q3	$109M	Sell	4,720,495 -1,094	-0%	-$25.9K	4.45%	4
2021 Q2	$118M	Buy	4,721,589 +1,589	+0%	+$42.7K	3.99%	4
2021 Q1	$132M	Buy	4,720,000 +260,000	+6%	+$9.38M	2.95%	8
2020 Q4	$156M	Buy	4,460,000 +1,080,627	+32%	+$47M	3.7%	7
2020 Q3	$166M	Hold	3,379,373	–	–	6.4%	3
2020 Q2	$153M	Buy	+3,379,373	New	+$147M	5.82%	3

Other funds holding FMTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Cormorant Asset Management's FMTX Position: Q3 2022 in Review

Cormorant Asset Management sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q3 2022, closing a stake of 3,172,204 shares — an estimated $21.9M sold.

Cormorant Asset Management first reported a position in FMTX in Q2 2020 and held it in 9 quarters. The position peaked at $166M in Q3 2020. 139 funds tracked by Wall St. Rank hold FMTX as of Q3 2022.

Cormorant Asset Management reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Cormorant Asset Management sold 3,172,204 Forma Therapeutics Holdings, Inc. Common Stock shares in Q3 2022, an estimated $21.9M.
Cormorant Asset Management first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q2 2020 and held it in 9 quarters.
Cormorant Asset Management's Forma Therapeutics Holdings, Inc. Common Stock position peaked at $166M in Q3 2020.
139 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on Cormorant Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.